[Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

By F. García-Bragado Dalmau. Revista clínica española (Ed. impresa), 2013

1,685 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. (2014, neutral): “Marini et al,26 1988 30 Urokinase (800 000 IU for 12 h/d for 3 d or 3 300 000 IU for 12 h) Heparin Not prespecified 7 a a a 30 (100) 53 (23-72) 18 (60)”
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “lactation, and in patients with antiphospholipid antibody syndrome.(260,261,312) 314 III C”
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2018, neutral): “9 Currently receiving cancer treatment§ 142 (70) 140 (69) Chemotherapy 120 (85) 113 (81) Radiotherapy 10 (7) 6 (4) Targeted therapy 22 (15) 21 (15) Endocrine therapy 15 (11) 15 (11) Primary tumor type Bladder 4 (2) 10 (5) Brain 2 (1) 1 (1) Breast 20 (10) 20 (10) Cancer unknown primary 3 (2) 3 (1) Ch”